Daniel H. Ahn, DO, discusses advancing actionable alterations in colorectal cancer.
Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses advancing actionable alterations in colorectal cancer (CRC).
The emergence of novel targeted therapies has reinforced the importance of molecular testing, says Ahn.
Historically, KRAS was the main actionable alteration in CRC, explains Ahn. However, BRAF, HER2, FGFR, NTRK, ROS1, and ALKaberrations have emerged in recent years.
Although some mutations occur in less than 1% of patients with CRC, when taken collectively, 25% to 50% of patients could harbor an actionable mutation, Ahn concludes.